Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;14(13):e70988.
doi: 10.1002/cam4.70988.

Understanding the Impact of Salvage Radiation on the Long-Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

Spyridon P Basourakos  1 , Stephen A Boorjian  1 , Phillip J Schulte  2 , Grant Henning  1 , Jamie T O'Byrne  2 , Matthew K Tollefson  1 , Igor Frank  1 , Abhinav Khanna  1 , Ryan M Phillips  3 , Bradley J Stish  3 , R Jeffrey Karnes  1 , Vidit Sharma  1
Affiliations

Understanding the Impact of Salvage Radiation on the Long-Term Natural History of Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

Spyridon P Basourakos et al. Cancer Med. 2025 Jul.

Abstract

Purpose: The natural history of biochemical recurrence (BCR) after radical prostatectomy (RP) remains understudied, with limited long-term data from large cohorts inclusive of both salvage radiotherapy (SRT)-treated and untreated patients. Herein, we sought to evaluate the outcomes of patients with BCR and the impact of SRT on disease progression.

Materials and methods: Patients undergoing RP who developed BCR (PSA ≥ 0.20 ng/mL) were included. Patients with BCR treated with SRT were compared to untreated patients using risk-set matching with time-dependent propensity scores. The primary outcome was metastases, analyzed using Kaplan-Meier and Cox models. The number needed to treat (NNT) with SRT to prevent progression was derived at 5 and 15 years.

Results: Among 6881 patients with BCR, 2109 received SRT. At a median follow-up of 10.2 years, 1147 patients developed metastases. The median PSA at the time of SRT was 0.50 ng/mL. After 1:1 propensity score matching (2109 patients per cohort), SRT significantly reduced the risk of metastases at 5 (12.7% vs. 19.3%, p < 0.0001) and 15 years (28.6% vs. 31.5%, p < 0.001). On multivariable analysis, SRT independently reduced metastasis risk (HR 0.75, 95% CI 0.63-0.90, p = 0.002), translating to NNT of 23 and 15 at 5 and 15 years, respectively. Interaction analyses between SRT and nodal status (p = 0.04) showed greater metastasis risk reduction in pN+ (HR 0.41, 95% CI 0.22-0.77, p = 0.005) compared to pN- disease (HR 0.81, 95% CI 0.67-0.97, p = 0.02).

Conclusions: Most patients with BCR post-RP do not progress to metastasis. For those who do progress, SRT inarguably improves the oncologic outcomes in the BCR setting. However, careful patient selection and shared decision making should be encouraged in order to limit overtreatment and side effects.

Keywords: biochemical recurrence; prostate cancer; salvage radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Vidit Sharma owns personal stock worth < $10,000 in ImmunityBio and Macrogenics. Stephen A. Boorjian is a consultant for Ferring, ArTara, Prokarium, and Johnson & Johnson.

Figures

FIGURE 1
FIGURE 1
Consort diagram of BCR cohort selection.
FIGURE 2
FIGURE 2
Cumulative incidence of (A) systemic progression, (B) prostate cancer‐specific mortality, and (C) overall mortality among 1:1 propensity score‐matched patients with BCR post‐RP, stratified by receipt of SRT versus no SRT.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Boorjian S. A., Thompson R. H., Tollefson M. K., et al., “Long‐Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time From Surgery to Recurrence,” European Urology 59 (2011): 893–899. - PubMed
    1. Ward J. F., Blute M. L., Slezak J., et al., “The Long‐Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical Prostatectomy,” Journal of Urology 170 (2003): 1872–1876. - PubMed
    1. Brockman J. A., Alanee S., Vickers A. J., et al., “Nomogram Predicting Prostate Cancer‐Specific Mortality for Men With Biochemical Recurrence After Radical Prostatectomy,” European Urology 67 (2015): 1160–1167. - PMC - PubMed
    1. Pound C. R., Partin A. W., Eisenberger M. A., Chan D. W., Pearson J. D., and Walsh P. C., “Natural History of Progression After PSA Elevation Following Radical Prostatectomy,” JAMA 281 (1999): 1591–1597. - PubMed
    1. Freedland S. J., Humphreys E. B., Mangold L. A., et al., “Risk of Prostate Cancer‐Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy,” JAMA 294 (2005): 433. - PubMed

MeSH terms

Substances